Search hospitals
>
Illinois
>
Peoria
Methodist Medical Center of Illinois
Claim this profile
Peoria, Illinois 61602
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Pancreatic Cancer
Conducts research for Prostate Cancer
Conducts research for Breast cancer
530 reported clinical trials
5 medical researchers
Summary
Methodist Medical Center of Illinois is a medical facility located in Peoria, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast cancer and other specialties. Methodist Medical Center of Illinois is involved with conducting 530 clinical trials across 524 conditions. There are 5 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Alexander Adler, MD, and Praveen Sudhindra, MD.
Area of expertise
Breast Cancer
Methodist Medical Center of Illinois has run 84 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Methodist Medical Center of Illinois has run 76 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
James L. Wade
Decatur Memorial Hospital
4 years of reported clinical research
Alexander Adler, MD
Methodist Medical Center of Illinois
4 years of reported clinical research
Praveen Sudhindra, MD
Methodist Medical Center of Illinois
2 years of reported clinical research
Clinical Trials running at Methodist Medical Center of Illinois
Lung Cancer
Prostate Cancer
Bladder Cancer
Breast Cancer
Colorectal Cancer
Pancreatic Cancer
Ovarian Cancer
Breast cancer
Esophageal cancer
Multiple Myeloma
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Methodist Medical Center of Illinois?
Methodist Medical Center of Illinois is a medical facility located in Peoria, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast cancer and other specialties. Methodist Medical Center of Illinois is involved with conducting 530 clinical trials across 524 conditions. There are 5 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Alexander Adler, MD, and Praveen Sudhindra, MD.
Where is Methodist Medical Center of Illinois located?
**Methodist Medical Center of Illinois Location:** To reach Methodist Medical Center of Illinois, take I-74 to Exit 94A. Head north on NE Glen Oak Ave, and you will find the hospital on your right at 221 NE Glen Oak Ave, Peoria, IL.
Who should I call to ask about financial aid or insurance network?
Methodist Medical Center of Illinois, now part of Carle Health, offers financial assistance to those with limited resources needing medical care. Patients can discuss payment options with the Financial Assistance Department by providing necessary documents like ID cards and doctor's orders. For insurance inquiries or Medicaid assistance, contact the Insurance Information department or the state Department of Health and Human Services.
What insurance does Methodist Medical Center of Illinois accept?
The Methodist Medical Center of Illinois, now part of the Carle Health system, accepts a wide range of health insurance plans. These include Medicare Part A & B, AARP Medicare Complete, UnitedHealthcare, TRICARE, Aetna, Anthem Blue Cross Blue Shield, Cigna, Humana Health Plans, ComPsych, United Behavioral Health Care, and Value Options. Additionally, state-issued insurances like the Healthy Indiana Plan, Hoosier Healthwise & Hoosier Care Connect, Hospital Presumptive Eligibility, Traditional Indiana Medicaid, Indiana Care Select, and Illinois Medicaid are accepted. For the most current information on accepted insurance plans, please visit the hospital's official website or contact them directly.
What awards or recognition has Methodist Medical Center of Illinois received?
Methodist Medical Center of Illinois, now part of Carle Health, has been awarded Magnet recognition for nursing excellence by the American Nurses Credentialing Center. It has also been recognized for its significant research contributions, maintaining its tax-exempt status since 1938 due to its involvement in various research projects.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.